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Abstract
Deoxycytidine kinase (dCK) phosphorylates 2'-deoxycyti-
dine, as well as the purine deoxyribonucleosides and a num-
ber of nucleoside analogues that are important in the chemo-
therapy of leukemias. The enzyme is highly expressed in the
thymus relative to other tissues and may play an important
role in the T cell depletion associated with adenosine deami-
nase and purine nucleoside phosphorylase deficiencies. To
characterize the dCK promoter region and to determine
whether it mediates higher levels of gene expression in T
lymphoblasts, we have analyzed a 700-bp genomic fragment
encompassing 548 bp of 5' flanking region for functional
activity and for transcription factor binding using T and B
lymphoblast cell lines and nuclear extracts. The regions of
the promoter that were defined as important to its function
include a 5'GC box, an E box, a 3'GC box, and an E2F
site. The transcription factor Spl binds to both GC boxes,
activating at the 5' site but repressing at the 3' site. MLTF/
USF activates transcription through the E box, whereas E2F
activates through the E2F site, but binds weakly to this site
in vitro and does not appear to mediate cell cycle-specific
expression of dCK in vivo. No significant differences in pro-
moter activity or transcription factor binding were observed
between Jurkat T and Raji B lymphoblasts. The promoter of
the dCK gene is thus regulated by a number of ubiquitously
expressed transcription factors. DCK expression in cultured
lymphoblast cell lines is not solely a function of the T or B
lineage derivation. (J. Clin. Invest. 1995. '95:1660-1668.)
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Introduction
Deoxycytidine kinase (NTP:deoxycytidine 5 '-phosphotransfer-
ase, EC 2.7.1.74; dCK)' catalyzes the phosphorylation of 2'-
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deoxycytidine to its 5'-monophosphate and, despite a much
higher Km for the purine deoxyribonucleosides, also plays a
major role in phosphorylating 2 '-deoxyadenosine and 2 '-deox-
yguanosine to their corresponding monophosphates ( 1-4).
dCK is also central in the activation of anticancer and antiviral
agents such as cytosine arabinoside, fludarabine, 2 ',3 '-dideoxy-
cytidine, and 2-chlorodeoxyadenosine (CdA) (5-9). Cell lines
lacking dCK activity are resistant to these nucleoside analogues
(10), whereas increased dCK activity has been associated with
increased sensitivity to these agents ( 11).
dCK also may play an important role in the pathogenesis
of the immunodeficiency syndromes associated with deficien-
cies of the purine catabolic enzymes adenosine deaminase
(ADA) and purine nucleoside phosphorylase ( 12). The prefer-
ential cytotoxicity of the ADA substrate, 2'-deoxyadenosine,
and the purine nucleoside phosphorylase substrate, 2'-deoxy-
guanosine, for human thymocytes has been thought to account
for the T cell depletion in these disorders. Cytotoxicity has
been attributed to the ability of thymocytes and human T
lymphoblasts to accumulate the corresponding 2'-deoxyribo-
nucleoside triphosphates from these substrates, resulting in inhi-
bition of DNA synthesis. Deoxyribonucleotide accumulation in
turn has been felt to result from the relatively high levels of
dCK and the low levels of 5 '-nucleotidase in these cells. Several
studies have demonstrated higher levels of dCK activity (13-
15) and mRNA (16) in human thymocytes and T lymphoblasts
than in other tissues, including EBV-immortalized B lym-
phoblasts, although normal peripheral blood T and B cells ap-
pear to contain similar amounts of dCK activity and immunore-
active protein (17).
To understand the molecular basis for tissue-specific regula-
tion of dCK activity in normal and neoplastic human cells, we
have cloned the dCK gene and identified its promoter (18).
The 5' region of the gene is highly GC rich and lacks TATA
or CAAT boxes. It does have an E2F site similar to those found
in the promoters of dihydrofolate reductase (DHFR), thymidine
kinase (TK), c-myc, and other genes important for the initiation
of DNA synthesis (19, 20). Preliminary transfection experi-
ments into transformed human T and B lymphoblast cell lines
revealed significantly higher levels of expression of this pro-
moter in T lymphoblasts. Since the regulation of expression of
this gene may directly relate to the chemosensitivity of neoplas-
tic cells to certain nucleoside analogs, we have further defined
the mechanisms responsible for its regulation in cultured
lymphoblast cell lines.
Methods
Deletion mutants. A 700-bp HindHII fragment spanning the promoter,
first exon, and 61 bp of the first intron was cloned into pCAT-Basic
(Promega, Madison, WI) to yield pCAT-Basic 700 (see Fig. 2). Diges-
tion of this construct with SmaI resulted in the removal of 183 bp of
5' sequence (pCAT-Basic 517). Removal of the first intron segment,
first exon, and most of the 5' untranslated region from pCAT-Basic
517 with Sacd produced pCAT-Basic 244. The 244-bp promoter was
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cloned into pUC CAT to take advantage of the Sacd and SmaI sites in
the multiple cloning site. Deletions were made from the 5' end after
digestion with Sacd and SmaI to create exonuclease-resistant and suscep-
tible ends, respectively, using an Exo III/Mung bean nuclease deletion
kit from Stratagene (La Jolla, CA). All deletion mutant plasmids were
prepared using Qiagen columns (Chatsworth, CA) and sequenced by
the dideoxy chain termination method (USB, Cleveland, OH).
Transfections. Jurkat T lymphoblasts and Raji B lymphoblasts were
grown in RPMI and 10% FCS. Cells were harvested during exponential
growth, washed in serum-free medium, and resuspended at 107 cells
per 400 y1 of RPMI. CAT plasmids (30 jug) and cytomegalovirus
(CMV)-lacZ or fi-actin-lacZ plasmids (courtesy of Lorraine Gudas,
Cornell University, NY) (10-30 dIg) were resuspended in 100 Il of
PBS and mixed with the cells. Electroporation was performed with a
Gene Pulser (Bio-Rad Laboratories, Richmond, CA) with 0.4-cm cu-
vettes at 250 V, 960 HF. Cells were harvested after 48 h, and extracts
were prepared by three freeze-thaw cycles and removal of insoluble
debris by centrifugation. For chloramphenicol acetyltransferase (CAT)
assays, 5-50-k1 aliquots of heated cell extracts (21) were assayed with
0.1 I Ci of ['4C]chloramphenicol and 25 pg of n-butyryl CoA in 125
ILI. Reactions were stopped with xylenes, and the reaction products were
extracted and counted (22). ,B-Galactosidase activity was measured in
unheated extracts using chlorophenol red /3-D-galactopyranoside as a
substrate (23).
Nuclear extracts. Extracts were made from exponentially growing
Jurkat and Raji cells by the method of Dignam et al. (24) with modifica-
tions as described by Blake et al. (25). Cells were homogenized in buffer
A (10 mM Hepes, pH 7.9, 0.75 mM spermidine, 0.15 m.M spermine, 0.1
mM EDTA, 0.1 mM EGTA, 10 mM KCl, 1 mM DTT, 1 mM PMSF),
and nuclei were sedimented by centrifugation at 30,000 g for 30 s.
Nuclear factors were then extracted in buffer C (20 mM Hepes, pH 7.9,
0.2 mM EDTA, 0.2 mM EGTA, 2 mM DTT, 20% glycerol, 0.15 mM
spermine, 0.75 mM spermidine, 1 m.M PMSF, 0.4 M NaCl). The extract
was subjected to centrifugation for 45 min at 300,000 g, followed by
dialysis in modified buffer D (20 mM Hepes, pH 7.9, 20% glycerol,
100 mM KCl, 0.2 mM EDTA, 0.2 mM EGTA, 2 mM DTT, 1 mM
PMSF, 12.5 mM MgCl2). The extracts were aliquoted and stored
at -700C.
DNase Ifootprinting. Three probes were prepared to span the region
from -450 to + 151 (relative to the translation start site) of the dCK
promoter. The first probe was prepared by digesting the 700-bp promoter
with PstI, end labeling with Klenow (taking advantage of its 3' - 5'
exonuclease activity), and digesting with BglI, yielding a 254-bp probe
spanning -450 to -197. A second probe was prepared by digesting the
promoter with NarI, incubating with calf intestinal alkaline phosphatase,
and labeling the ends with T4 polynucleotide kinase or Klenow. This
labeled DNA was then cut with MaelH, yielding a 217-bp probe span-
ning -299 to -83. A third probe was prepared by digesting the promoter
with HindIl, labeling with Klenow, and digesting with CfrlOI. This
last 291-bp probe spanned the region between -140 and + 151. Probes
were electrophoresed on nondenaturing polyacrylamide gels and eluted
by the "crush and soak" method (26). DNase footprinting was per-
formed according to Blake et al. (25). 5-10 ng of end-labeled DNA
was incubated with nuclear extract in the presence of 15 yg of poly (dl-
dC) in a 120-,lI volume containing 6.1% glycerol, 0.07 mM EDTA,
0.07 mM EGTA, 7.2 mM Hepes, pH 7.9, 39 mM KCl, 7.5 mM MgCI2,
and 0.7 mM DTT. The binding reaction mixtures were incubated on ice
(for kinase-labeled probes) or at room temperature for 30 min. CaCI2
(2 mM final concentration) was added, and protein-DNA complexes
were digested with DNase I (Worthington Enzymes, Freehold, NJ) for
4 min at room temperature. Purified Spl was purchased from Promega,
and footprinting reactions were done according to the Promega protocol.
Digestions were stopped by adding 2 vol of a mix containing 100 mM
Tris, pH 8, 20 mM EDTA, 0.1% SDS, 100 yg/ml proteinase K, and
100 ILg/ml glycogen. After incubation at 37°C for 20 min, the samples
were extracted with phenol-chloroform and precipitated with ethanol.
Samples were resuspended in formamide loading dye and run on 6%
sequencing gels.
Site-directed mutagenesis. Mutagenesis of the promoter was accom-
plished by the method of Kunkel et al. (27) with the 3 'GC-M, oligonu-
cleotide, or by recombinant PCR (28). Sense-strand mutagenic primers
are shown below, with the consensus transcription factor-binding sites






Oligonucleotidesubstitutions were designed as reported previously (25,
29-31), or were shown not to bind the relevant transcription factor by
gel-shift assays. 7-Deaza-dGTP (1:1 with dGTP) was used to amplify
the GC-rich promoter, and Pfu DNA polymerase (Stratagene) was used
to maximize fidelity of DNA synthesis. Promoter fragments containing
the designated substitutions were cloned into pCAT-Basic at the SalI
site. All plasmids were prepared using Qiagen columns and sequenced.
Gel-shift assays. The sequences of the wild-type sense oligonucleo-
tides are shown below, with the consensus transcription factor-binding
sites underlined:








Oligonucleotides were annealed, end labeled with Klenow, and purified
on NENSORB columns (Du Pont NEN, Boston, MA). For most experi-
ments, 0.2 ng of probe was incubated with 4-10 jug of nuclear extract
in 12 mM Hepes, pH 7.9, 60 mM KCI, 0.6 mM DTT, 1 mM EDTA,
12% glycerol, 1 mM MgCl2, and 2 gg of poly(dI-dC) in 20 IlI (32).
For E2F gel shifts, the incubation buffer consisted of 20 mM Hepes,
pH 7.8, 1 mM MgCl2, 0.1 mM EDTA, 40 mM KCl, 0.5 mM DPI',
1.5% NP-40, 1% Ficoll, 2 jtg of salmon sperm DNA, and 60 pg of BSA
(33). Incubations were allowed to go for 20 min at room temperature. If
competitor oligonucleotides were used, they were allowed to preincubate
on ice for 10 min before addition of the probe. With antibodies, the
preincubation time was 2-4 h on ice. With purified Spl, 10 ,ug of BSA
was included in the incubation. Anti-Sp1 antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA), and anti-USF was pro-
vided by Robert Roeder (The Rockefeller University, New York). Bind-
ing reactions were resolved on 4% (30:1 acrylamide/bis) nondenaturing
Tris-glycine-2.5% glycerol or 0.5x Tris-borate-EDTA minigels.
Gels were run at 100 V, dried, and autoradiographed.
Nuclear run-on assays. Single-stranded probes for portions of exon
1 (322 bases), intron 2 (400 bases), and exon 6 (422 bases) were
prepared by cloning into M13mpl 8 or M13mpl9. All other probes were
prepared from cDNAs in double-stranded plasmids. Cells (5 x 107) in
exponential growth were harvested, washed in PBS, resuspension buffer
(10 mM Tris, pH 7.4, 10 mM NaCl, 5 mM MgCl2), and resuspension
buffer + 0.5% NP-40. Nuclei were then resuspended in 210 p1 of nuclear
freezing buffer (50 mM Tris, pH 8.3, 40% glycerol, 5 mM MgCl2, 0.1
mM EDTA). 60 1l of Sx run-on buffer (25 mM Tris, pH 8.0, 12.5
mM MgCl2, 750 mM KCl, 1.25 mM each of ATP, CTP, and GTP) and
30jul (300 ,uCi) of [a-32P]UTP were added, and labeling was allowed
to proceed for 30 min at 30°C, with intermittent mixing. Nascent RNA
was isolated with Tri Reagent (Molecular Research Center, Cincinnati,
OH) according to Srivastava et al. (34). RNA was cleaved for 10 min
at 4°C with 0.2 M NaOH, neutralized with Hepes buffer (0.48 M), and
precipitated with ethanol. Blots were prepared by loading S gg of alka-
line-denatured plasmid directly onto a Zeta-Probe membrane (Bio-Rad
Laboratories), using a slot-blot apparatus. Equivalent amounts of la-
beled RNA were hybridized to the blots in 0.25 M NaH2PO4, pH 7.2,
7% SDS for 2 d at 65°C. Blots were washed with 10 ,ug/ml RNase A
in 2x SSC for 30 min at 37°C. Final washes were in 0.1X SSC, 0.1%
SDS at 65°C. After autoradiography, blots were placed in a phosphorim-
ager screen for quantitation.
Northern blots. RNA was prepared with Tri reagent and dissolved
in Formazol (Molecular Research Center). In mRNA stability experi-






5'GC box E box
-347 TGGGGTAGAGGCCTTCCGCCACACGCGCGGCCCCGCCCCGGCCT CAMGT
GACCTG/ GCGTGCGGAGCGCGCAGCGGGAACCCGCGCTGGAGGCGGGCGAG
3 ' GC box
-247 GGCCGAGGGGCAGCTAGG/GAGCGCGGCTTGAGEGGGGCGGGGCCGCCCCG
E2F I
CAGGCCCGCCAGT/GTCCTCAGCTGCCTCCGCGCGC CAAAGTCAAA/CCCCG Figure 1. Sequence of the human
Sac I dCK gene promoter, from Song et al.
(18). Boundaries of the deletion mu-
-147 ACACCCGCCGGCGGGCCGGTGAGCTC/ACTAGCTGACCCGGCAGGTCAGGA tants (/) and DNase I-protected re-
TCTGGCTTAGCGGCGCCGCGAGCTCCAGTGCGCGCACCCGTGGCCGCCTC gions (italics) are shown. Consensus
sites for transcription factor binding
+1 are underlined. The arrow indicates
-47 CCAGCCCTCTTTGCCGGACGAGCTCTGGGCCGCCACAAGACTAAGGAATG the putative transcription start site,
and +1 refers to the A of the ATG
GCCACCCCGCCCAAGAGAAGCTGCCCGTCTTTCTCAGCCAGCTCTGAGGG initiator codon. Bold letters indicate
+54 GACCCGCATCAAGAAAATCTCCATCGAAGGGAACATCGGTAAGGAGccTccGGA additional bases in this revised se-
quence. Smaller letters indicate intron
AATGTGGGACGCAAGGCTGGGGTGTCGCGGCAGTGGCTGAAGCTT 1 sequence.
ments, actinomycin D (5 /ig/ml) was added to the cells. Total RNA
(10 /ig per lane) was fractionated in denaturing formaldehyde-agarose
gels and then transferred to nylon membranes. A truncated version of
the full-length dCK cDNA (clone G) (16) was labeled by the random
primer method (35), and hybridization was performed in High Effi-
ciency Hybridization Buffer with formamide (Molecular Research Cen-
ter) overnight at 420C. Final washes, autoradiography, and quantitation
were performed as previously described. 28S rRNA oligonucleotide
was labeled with [y-32P]ATP and T4 polynucleotide kinase. The blot
stripped of dCK probe was hybridized overnight at 37°C and washed
several times with 5x SSPE, 0.1% SDS at 50°C.
dCK activity assay. The assay was performed using CdA (0.5 jLM
[8-3H]CdA, 49.5 uM unlabeled CdA) as a substrate ( 15). [8-3H]CdA
was purchased from Moravek Biochemicals (Brea, CA), and unlabeled
CdA was obtained from Ortho Biotech (Raritan, NJ). Linearity was
maintained with up to 30 lug of protein per 50 pl for at least 1 h.
Results
We demonstrated previously that a 700-bp HindII fragment
from the dCK gene possesses promoter activity upon transfec-
tion into human lymphoblast cell lines, with 12-19-fold higher
activity in Jurkat T lymphoblasts than in Raji B lymphoblasts
after normalizing for transfection efficiency with cotransfection
of CMV- or Rous sarcoma virus (RSV)-IacZ (18). Fig. 1
shows the sequence of this fragment, corrected with the addition
of 3 bases at -292, -144, and -140. To delineate basal ele-
ments and to explore possible cell-specific elements in the pro-
moter, we analyzed a series of deletion mutants for promoter
activity (Fig. 2). Deletion of 183 bp of 5' sequence (pCAT-
Basic 517) increased promoter activity by two- to threefold.
Deletion of 273 bp from the 3' end removed much of the 5'
untranslated sequence, the first exon, and the first intron seg-
ment (pCAT-Basic 244). This fragment produced 20-25% of
the CAT activity of pCAT-Basic 517, despite the removal of
the competing translation start site from the dCK gene. When
serial exonuclease deletions were made from the 5' end of the
244-bp promoter, a 50-70% drop in CAT activity occurred
after the removal of 74 bp. The deleted segment contained a
GC-rich consensus SpI site (5 'GC box) and an E box. Further
deletions did not cause further decreases in promoter activity.
The CAT activity profiles of the deletion mutants in Jurkat
as compared with Raji cells were identical when portrayed as
a percentage of 244-bp promoter activity in their respective
cells. However, the CAT/,B-galactosidase ratios in Jurkat cells
were 100- 1,000-fold higher than those in Raji cells. This differ-
ence could not be accounted for by a difference in transfection
efficiency, since ,B-galactosidase activities from cotransfected
constructs driven by CMV, RSV, or,B-actin promoters were
always higher in Raji cells. Since the background CAT activities
from a series of CAT vectors (pUC CAT, pCAT-Basic, pBS
CAT) were always higher in Jurkat cells, we speculate that a
common vector element outside the promoter mediates in-
creased expression in these cells. These data support the concept
that the regulation of the dCK promoter does not differ in these
model T and B lymphoblast cell lines.
We used DNase I footprinting analysis to identify sites of
transcription factor binding within the dCK promoter. Three
probes were used to span the promoter from -450 to + 151.
The first probe, extending from -450 to -197, demonstrated
an extended footprint from -327 to -291 (Fig. 3 A), the region
that encompasses the 5 'GC box and the E box. A second pro-
tected region was observed from -221 to -197, corresponding
to the 3'GC box. This footprint was also detected using the
probe from -299 to -83 (Fig. 3 B). The region encompassing
the E2F site was difficult to evaluate since it was resistant to
DNase I digestion in the absence of nuclear extract, although
1662 Chen et al.
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Figure 2. Transfection of promoter
constructs into Jurkat and Raji cells.
Deletions were made by restriction
endonuclease or exonuclease III di-
gestion. Cells were transfected with
CAT and lacZ plasmids by electro-
poration and harvested 2 d later. En-
zyme assays were performed as de-
scribed in Methods. CAT activities
were normalized to /i-galactosidase
activities to control for transfection
efficiency and are shown relative to
that of the 244-bp promoter in each
cell type. In the schematic diagram of
the constructs, open boxes represent
the 5' untranslated region and closed
boxes represent the coding region of
exon 1. Bases are numbered relative
to the translation start site. Bars, rep-
resenting mean±SD, are the results of
two independent experiments done in
duplicate.
hypersensitive sites were clearly observed on either side of the
E2F site with DNase I digestion (Fig. 3 B). Similar resistance
to DNase I cleavage has also been observed at the E2F site of
the hamster DHFR gene (29). No sites of protection from or
hypersensitivity to DNase I digestion were detected in the region
from -140 to + 151 (data not shown). DNase I footprints were
identical using either Jurkat or Raji nuclear extracts.
The functional significance of the protected regions was
evaluated by in vitro mutagenesis and transfection analysis.
Four regions were independently mutated: the 5'GC box, E
box, 3 'GC box, and E2F site. As shown in Fig. 4, mutation of
the 5 'GC box reduced CAT activity by 50-70% relative to the
wild-type 244-bp promoter. Mutation of the E box decreased
CAT activity by 50%. In our E box mutant, we mutated
CACGTG to CACGAC to prevent basic helix-loop-helix
(bHLH) transcription factors from binding (31 ). This mutation
inadvertently created a new E box, CACGACACCTG, but the
consistent reduction in CAT activity strongly suggests that it
cannot substitute for the native site. A 5-bp substitution of the
3 'GC box (MI) caused an unexpected increase in CAT expres-
sion that was more modest in Jurkat cells (150% of wild type)
than in Raji cells (250% of wild type). To confirm this result,
we changed and extended the mutation at this site by replacing
10 bases (3 'GC-M3). CAT activity remained consistently above
that of the 244-bp native promoter (200-270%). Mutation at
the E2F site reduced promoter activity by 30-60%, suggesting
a functional role for this region.
Gel-shift analysis was performed to identify the specific
transcription factor(s) binding to these regions. The 5 'GC and
E boxes were included in one oligonucleotide probe. Incubation
of this probe with either Jurkat or Raji nuclear extracts yielded
three bands (Fig. 5 A). The top and bottom bands were com-
peted by an unlabeled 22-bp oligonucleotide with a perfect SpI
consensus sequence, a result consistent with the known doublet
pattern of Spl in gel-shift assays (30). The middle band was
competed by an oligonucleotide containing the CACGTG se-
quence from the adenovirus major late promoter. Although the
S 'GC box and the E box formed one extended footprint, these
gel-shift results suggest that SpI and USF do not bind coopera-
tively; no conclusions can be made about competitive interac-
tions. Antibody to SpI supershifted the SpI complexes, whereas
anti-USF antibody prevented protein binding to the E box. Spl
also bound to the 3'GC box (Fig. S B) with the expected
competition and antibody supershift patterns. When the E2F
site of the dCK promoter was used in a gel-shift assay, no
shifted bands were apparent (data not shown). Using the same
conditions, a 29-bp dyad E2F site from the hamster DHFR
promoter did shift (Fig. 5 C). The dCK E2F site was able to
compete for binding with the DHFR E2F probe, but was not as
strong a competitor as the DHFR E2F site oligonucleotide.
Identical results were obtained with a second dCK E2F competi-
tor that had 14 bp instead of 5 bp of 5' sequence to control for
the presence of a nonconsensus dyad site. No differences in
protein binding were observed with any of the probes between
Jurkat and Raji nuclear extracts.
Since no significant differences were observed in dCK pro-
moter activity or protein binding between Jurkat and Raji cells,
we performed nuclear run-on transcription assays to measure
directly the relative levels of dCK transcription in these cells
(Fig. 6 A). Exon 1 transcription was easily detected with a
single-stranded probe to the sense strand. No transcription was
detected through intron 2 and exon 6, suggesting increased RNA
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Figure 3. DNase I footprint analysis of the dCK promoter. DNA probes from -450 to -197 (A) and -299 to -83 (B) were end labeled, purified,
and incubated with the indicated amount of Jurkat or Raji nuclear extract before DNase I digestion. Cleavage products were separated on a 6%
denaturing acrylamide gel along with the corresponding dideoxy sequencing reaction. Boxes indicate consensus sequences for transcription factor-
binding sites, and the arrow indicates the putative transcription start site.
polymerase density at exon 1 and/or transcription arrest/attenu-
ation between exon 1 and intron 2. Opposite strand transcription
was undetectable using exon 1, intron 2, and exon 6 probes
(data not shown). This result was reproducible using either [a-
32P]UTP or [a-32P] CTP, with NaOH cleavage of transcripts
before hybridization and RNase A in the wash for maximum
specificity. Unexpectedly, exon 1 transcription was higher in
Raji than in Jurkat cells. Controls included ,6-actin and ADA,
which is transcribed at high levels in T lymphoblasts (36).
Northern blots of dCK steady-state mRNA levels (Fig. 6 B)
and enzyme activities (Fig. 6 C) correlated with the exon 1
transcription data. Measurements of the dCK mRNA half-life
after actinomycin D treatment demonstrated equivalent values
of 2-4 h in Jurkat and Raji cells (data not shown). dCK mRNA
and specific activity levels were also measured in MOLT-4
and hypoxanthine-guanine phosphoribosyltransferase-deficient
CEM AB9228 T lymphoblasts and the EBV-immortalized B
lymphoblast lines GM558 and MGL-8 (Fig. 6, B and C). It is
apparent that Raji transformed B lymphoblasts have signifi-
cantly more dCK mRNA and activity than do the EBV-immor-
talized cells from peripheral blood.
Discussion
Although it has been shown that thymocytes and T lymphoblasts
have high dCK activity in relation to most nonlymphoid tissues
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Mutated dCK Promoter Site
Figure 4. Transfection of site-specific mutant constructs into Jurkat
(stippled bars) and Raji (solid bars) cells. The sequence alterations in
the mutant constructs are described in Methods. 3 'GC-M, and 3 'GC-
M3 contain two different mutations at the same site in the dCK promoter.
CAT activities were normalized to P-galactosidase activities and are
represented as a percentage of the wild-type 244-bp promoter. Bars
represent mean±SD of two separate experiments done in duplicate.
(13, 15), it was unclear whether T cells had more activity
than B cells. Early studies demonstrated that thymocytes and T
lymphoblasts were more sensitive to 2'-deoxyadenosine and
2'-deoxyguanosine toxicity than B lymphoblasts (37, 38). It
was postulated that high levels of dCK activity, coupled with
low cytoplasmic 5'-nucleotidase or other catabolic activity,
trapped purine deoxyribonucleotides intracellularly (13). The
accumulation of these purine deoxyribonucleotides could then
result in cytotoxicity by a variety of possible mechanisms, in-
cluding inhibition of ribonucleotide reductase, DNA nicking
and subsequent depletion of nicotinamide adenine dinucleotide,
ATP depletion, or inhibition of transmethylation reactions ( 12).
The literature on T versus B cell dCK activity is somewhat
contradictory, and interpretation of the results is dependent on
a critical examination of how the assays were done and which
cells were used. dCK activity is regulated by dCTP, ADP, and
other metabolites (4); furthermore, several other enzymes such
as cytidine deaminase, 5 '-nucleotidase, phosphatases, and thy-
midine kinase 2 greatly influence product formation (15). Al-
though thymic lymphocytes have high dCK activity, activities
in other lymphocyte populations vary. Tonsillar, splenic, and
peripheral blood T and B lymphocytes in particular have lower
dCK activities (39-41). If cultured cell lines are used, malig-
nant transformation and extent of differentiation must be consid-
ered in addition to lineage (42).
Our earlier studies demonstrated both 5-10-fold higher lev-
els of dCK mRNA in MOLT-4 and Jurkat T lymphoblasts than
in EBV-immortalized B lymphoblasts (16) and many-fold
higher levels of CAT activity when the dCK promoter-CAT
construct was transfected into Jurkat T as compared with Raji
B lymphoblasts (18). The use of the Raji cells in the latter
experiments was dictated by their high degree of transfectabil-
ity. We now believe this difference in dCK reporter gene activity
to be an artifact for the following reasons: (i) all dCK promoter
deletion mutants, as well as the promoterless pCAT-Basic vec-
tor, expressed much more CAT enzyme in Jurkat than in Raji
cells; (ii) Raji cells have 30-40% more dCK mRNA than Jurkat
cells, as determined by Northern analysis; and (iii) nuclear run-
on assays demonstrated that transcription of the exon 1 region
of the gene is proportional to steady-state mRNA levels in both
cell lines. Of note here is the marked disparity between Raji
B lymphoblasts and EBV-immortalized B lymphoblasts from
normal individuals. The Raji cell line was derived from a Bur-
kitt's lymphoma (43) and has undergone malignant transforma-
tion. In contrast, the EBV-infected cells have been immortal-
ized, but are not neoplastic. It is of interest that the Raji B
lymphoblasts are akin to T lymphoblasts in their sensitivity to
deoxyadenosine and their ability to accumulate purine deoxyri-
bonucleotides (42, 44). Whether or not these features result
from differences in dCK expression remains uncertain. These
data do emphasize the difficulty in extrapolating from cultured
cell lines to normal lymphocytes at different stages of develop-
ment.
We have analyzed the 700-bp promoter of the dCK gene in
detail. Four elements in the dCK promoter appear to be of major
importance in mediating gene transcription. The GC boxes cen-
tered at -313 (5'GC box) and -210 (3'GC box) bind Spl,
and mutation at the 5' site results in significantly less functional
activity. Surprisingly, Spl apparently acts as a repressor at the
3 'GC box. Review of the sequence immediately 3' to this site
revealed a perfect AP2 consensus sequence, and it is possible
that inhibition of Spl binding is permissive of AP2 activation.
Other examples can be cited in which Spl exerts primarily
repressor activity. Spl and the stage selector protein (SSP)
compete for overlapping sites in the human y-globin gene pro-
moter. In fetal erythroid cells, SSP activates the y-globin gene
promoter, whereas in adult erythroid cells, Spl binding is en-
hanced, preventing SSP from binding and thus reducing expres-
sion of the y-globin gene (45).
The third promoter element, the E box centered at -300,
was protected from DNase I digestion in a continuous footprint
with the 5 'GC box, but protein binding and transcriptional acti-
vation are independent of Spi. The bHLH protein binding to this
E box is presumably MLTF/USF, since the anti-USF polyclonal
antibody abolished DNA binding. It remains possible that other
members of the bHLH family interact with this E box in vivo,
or that MLTF/USF heterodimerizes with other bHLH proteins.
MLTF/USF binding and transcriptional activation can be fur-
ther regulated by methylation of the E box, with methylation
having a negative effect (46). This finding may have particular
relevance to dCK, since lack of dCK gene expression in an
cytosine arabinoside-resistant HL-60 cell line could be partially
restored with the demethylating agent 5-azacytidine (47).
The fourth promoter element, the E2F half-site, did not
footprint well, and protein binding to this region could be de-
tected only indirectly in a gel-shift assay. Nevertheless, DNase
I digestion clearly revealed a hypersensitive site, and mutation
within this site decreases promoter activity by - 50%. Although
E2F may play a role in basal dCK expression, there is no evi-
dence to support the cell cycle-specific regulation of dCK tran-
scription. Arner et al. have shown that dCK specific activity is
constitutively high and does not increase by more than twofold
during the cell cycle using resting and activated peripheral blood
lymphocytes or elutriated CEM T lymphoblasts (15, 48).
Hengstschlager et al. have measured dCK activity and mRNA
in elutriated cells, and in two of four cell lines tested, there was
a 10-15-fold increase in dCK activity beginning at the GI/S
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Figure 5. Gel-shift analysis of the 5 'GC and E boxes, the 3 'GC box, and the E2F site. (A) A single probe containing both the 5 'GC and E boxes
was incubated with Jurkat or Raji nuclear extract. Where indicated, competitor oligonucleotides had been preincubated with the extract before the
addition of probe. The Sp oligonucleotide contains a perfect consensus sequence for SpI; the adenovirus major late promoter (AdMLP) oligonucleo-
tide contains the E box known to bind MLTF/USF. In the middle panel, the 5 'GC and E box probe was added to nuclear extract or purified Spl
(2 fpu) that had been preincubated with or without anti-Sp1 antibody. In the right panel, the 5 'GC and E box probe was used with nuclear extract
and anti-USF antibody. Binding reactions were separated on 4% nondenaturing acrylamide gels, which were then dried and exposed to film for 1-
2 d. (B) Analysis of the 3 'GC box. Unless otherwise indicated, Jurkat nuclear extract was used. Competitor oligonucleotides or anti-Spl antibody
was used as indicated. (C) Analysis of the E2F site. Binding to the DHFR probe was competed using a mutant E2F site, the dCK E2F half-site,
or the DHFR E2F dyad site. With all three probes, identical competition patterns were observed with Jurkat and Raji nuclear extracts.
boundary; however, in none of the four cell lines were there
changes in dCK mRNA levels (49). Finally, we have found no
difference in steady-state dCK mRNA levels between resting
and activated peripheral blood T cells (50). Thus, dCK tran-
scription is not cell cycle regulated, despite its functional simi-
larity with the other cell cycle-regulated enzymes that modulate
deoxyribonucleotide metabolism, including TK, DHFR, and ri-
bonucleotide reductase.
In contrast to the dCK E2F half-site, the most well-charac-
terized E2F sites in the adenovirus early region 2 (E2), DHFR,
TK, and c-myc promoters contain overlapping or nonoverlap-
ping dyad sites ( 19, 20). Double mutations of the E2F sites in
cellular genes abolish GI /S regulation either by preventing GI/
S induction (51-53) or by making the promoter constitutively
active (54-57). When the DHFR dyad site is mutated to a half-
site, it still binds E2F and is activated by adenovirus ElA or
human CMV immediate early proteins (33, 58). However,
when the human TK promoter is mutated so as to contain only
a half-site, it binds E2F poorly, if at all, and GI IS induction is
lost (59). In the case of dCK and its half-site, the issue is not
so much lack of Gl/S induction, but lack of repression during
GO. We postulate that the lack of repression during GO is due
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Figure 6. Endogenous dCK expression in T and B lymphoblast cell
lines. (A) Nuclear run-on analysis of dCK transcription in Jurkat and
Raji cells. Nuclei were isolated and incubated with [32P]UTP for 30
min. Nascent transcripts were purified and subjected to limited hydroly-
sis with NaOH; equivalent amounts from each cell line were used for
hybridization to the blots. Each blot contained 5 yg of single-stranded
dCK gene fragments in M13 and denatured double-stranded plasmids
with ADA and,/-actin cDNAs. After a 2-d hybridization, the blots were
briefly washed with 10 Mlg/ml RNase A. Final washes were in 0.1 X
SSC, 0.1% SDS at 65TC. Typical autoradiography exposure times were
5 d. (B) Northern blot measuring steady-state dCK mRNA levels in T
and B lymphoblast cell lines. Total RNA (10 Mg per lane) was electro-
phoresed, transferred to nylon, and sequentially hybridized to dCK
cDNA and 28S rRNA oligonucleotide probes. Exposure times for dCK
were several hours to overnight and under 60 min for 28S. (C) dCK
enzyme activity in the various cell lines, measured using CdA as a
substrate according to Arn& et al. (15).
to the weak binding of E2F repressor complexes to the dCK
half-site, but other members of the E2F family or associated
proteins (60) not involved in cell cycle regulation may be im-
portant as positive factors for basal dCK promoter function.
The question of why dCK and TK, two functionally similar
enzymes in the deoxyribonucleoside salvage pathway, diverge
in cell cycle expression is an interesting one; the difference may
result from the presence of only one E2F half-site in the dCK
promoter.
Although this study has resulted in the delineation of the
basic elements regulating dCK transcription, the mechanism
underlying high level thymic gene expression remains obscure.
Elucidation of this mechanism will be important, since pharma-
cologic modulation of dCK expression could well play a role
in enhancing the chemotherapeutic sensitivity of malignant cells
to a number of nucleoside analogues. Future studies will be
directed at elucidating the role of enhancer elements in dCK
tissue-specific expression.
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